Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
03
05
2021
revised:
08
10
2021
accepted:
01
12
2021
pubmed:
16
12
2021
medline:
30
3
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
ROS1 fusion proteins resulting from chromosomal rearrangements of the
Identifiants
pubmed: 34907086
pii: 1535-7163.MCT-21-0395
doi: 10.1158/1535-7163.MCT-21-0395
pmc: PMC8828706
mid: NIHMS1763753
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-346Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233495
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Clin Cancer Res. 2020 Jun 15;26(12):2932-2945
pubmed: 32122926
Clin Cancer Res. 2016 May 15;22(10):2351-8
pubmed: 26673800
Cancer Res. 2011 Jul 15;71(14):4920-31
pubmed: 21613408
N Engl J Med. 2015 Feb 12;372(7):683-4
pubmed: 25671264
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90
pubmed: 26372962
Nat Commun. 2019 Aug 9;10(1):3604
pubmed: 31399568
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
J Clin Oncol. 2019 Jun 1;37(16):1370-1379
pubmed: 30892989
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19519-24
pubmed: 24218589
Mol Cancer Ther. 2016 Apr;15(4):628-39
pubmed: 26939704
Int J Mol Med. 2014 Jul;34(1):3-12
pubmed: 24820650
JCO Precis Oncol. 2017;2017:
pubmed: 29333528
Cancer Res. 2019 Feb 1;79(3):546-556
pubmed: 30538120
Clin Cancer Res. 2020 Sep 15;26(18):4785-4794
pubmed: 32591465
Lancet Oncol. 2020 Feb;21(2):261-270
pubmed: 31838015
Commun Biol. 2020 Dec 16;3(1):776
pubmed: 33328556
J Med Chem. 2010 Apr 8;53(7):2681-94
pubmed: 20000735
Pharmacol Res. 2016 Jan;103:26-48
pubmed: 26529477
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Cancer Discov. 2014 Jun;4(6):662-673
pubmed: 24675041
JCO Precis Oncol. 2019 Jun 3;3:
pubmed: 32914039
J Thorac Oncol. 2017 Nov;12(11):1611-1625
pubmed: 28818606
Pharmacol Res. 2021 Mar;165:105463
pubmed: 33513356
Annu Rev Biochem. 2011;80:769-95
pubmed: 21548788
N Engl J Med. 2013 Jun 20;368(25):2395-401
pubmed: 23724914
Clin Cancer Res. 2021 May 15;27(10):2899-2909
pubmed: 33685866
Cell. 2021 May 13;184(10):2649-2664.e18
pubmed: 33848463
Curr Opin Cell Biol. 2011 Aug;23(4):377-82
pubmed: 21592758
Cancer Discov. 2016 Jan;6(1):96-107
pubmed: 26554404
Curr Opin Oncol. 2007 Jan;19(1):55-60
pubmed: 17133113
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
Chem Commun (Camb). 2021 Feb 7;57(11):1344-1347
pubmed: 33432937
Clin Cancer Res. 2015 Jan 1;21(1):166-74
pubmed: 25351743
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6818-6827
pubmed: 30867294
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55
pubmed: 32760015
Clin Cancer Res. 2020 Jul 1;26(13):3287-3295
pubmed: 32269053
Cancer Res. 2010 Dec 15;70(24):10038-43
pubmed: 21030459
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Clin Cancer Res. 2018 Jul 15;24(14):3334-3347
pubmed: 29636358
Lancet Oncol. 2019 Dec;20(12):1691-1701
pubmed: 31669155
Clin Cancer Res. 2016 Dec 15;22(24):5983-5991
pubmed: 27401242